Robert Iannone, EVP, Global Head of R&D & CMO at Jazz Pharmaceuticals plc (JAZZ), sold 76,921 shares at $247.86 ($19.2M) on 2026-08-27, disclosed to the SEC on 2026-08-31.
Scheduled sale ($19.2M) by EVP, Global Head of R&D & CMO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $247.86 | 18,187 | $4.5M | 23.5% |
| 2 | $248.67 | 11,423 | $2.8M | 14.8% |
| 3 | $250.02 | 18,113 | $4.5M | 23.6% |
| 4 | $250.60 | 19,639 | $4.9M | 25.6% |
| 5 | $251.95 | 9,259 | $2.3M | 12.1% |
| 6 | $252.76 | 300 |
| $76K |
| 0.4% |
| Total | $249.70 avg | 76,921 | $19.2M | 100% |
| Filing → |
| JAZZ | SELL | 2025-03-07 | $1.7M | — | Filing → |
| JAZZ | SELL | 2022-12-13 | $559K | — | Filing → |